This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Advances One of Two Hep C Drugs

CAMBRIDGE, Mass. ( TheStreet) -- Vertex Pharmaceuticals (VRTX - Get Report) is advancing one experimental hepatitis C drug into mid-stage clinical trials while shutting down work on a second drug due to poor efficacy, the company announced Tuesday.

Both Vertex drugs, ALS-2200 and ALS-2158 belong to the class of hepatitis C drugs known as nucleotide (or nucleoside) polymerase inhibitors -- commonly referred to as "nucs" -- which have the potential to become the backbone of new, all-oral combination regimens.

The current superstar of the "nuc" drug class is Gilead Sciences' (GILD - Get Report) GS-7977, but Bristol-Myers Squibb (BMY - Get Report) was forced to abandon its nuc BMS-094 because it caused heart failure. The fallout from Bristol's drug has since spread to Idenix Pharmaceuticals (IDIX) and its nuc IDX-184, which is on clinical hold until U.S. regulators are assured the drug is safe.

The combination of ALS-2200 plus ribavirin yielded a 4.2 log10 reduction in viral load after seven days of dosing in previously untreated, genotype 1 hepatitis C patients. Eight patients were treated, of which five were able to achieve undetectable levels of the hepatitis C virus, Vertex announced Tuesday.

Vertex also disclosed that the "uridine" chemical structure of ALS-2200 is the same as Gilead's GS-7977. This is important since the recent safety issues related to nucs appear to be limited to those drugs with a "purine" chemical structure.

Based on these results, Vertex plans to move ALS-2200 into two, phase II studies. One study will evaluate ALS-2200 in combination with ribavirin, the other study will combine ALS-2200 with Vertex's currently marketed hepatitis C drug Incivek. Vertex is discussing the new studies with regulatory agencies and hopes to begin enrollment before the end of the year.

While Vertex is making progress towards developing an all-oral regimen for hepatitis C, the work being done by Gilead and others is still considerably in the lead. Vertex's ALS-2200 may also be less potent than GS-7977.

Vertex's ALS-2158 will not be moving ahead into new studies due to insufficient antiviral activity, the company said.

Vertex shares were down 1.5% to $57.86 in early Tuesday trading.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IDIX $24.50 0.20%
BMY $71.13 0.00%
GILD $87.17 0.00%
VRTX $82.16 0.00%
AAPL $95.18 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs